We have recently demonstrated that inhibitors of MTH1 (which inhibit the growth of the M121218 PDX model [18]), Pim kinases [19], Aurora kinases [20] and Chk1 kinases [21] are promising anti-cancer drugs; however, because these drugs lack a biomarker of response, they will most likely require pre-selection of patients using a platform such as the one described here for the clinical trial to be successful. This evidence concerns the gene NUDT1 and cancer.